When does the Paxlovid patent expire?
Paxlovid (nirmatrelvir/ritonavir) has multiple intellectual-property assets covering different aspects of the product, so “the” patent expiry depends on which specific patent or exclusivity period you mean. DrugPatentWatch.com tracks these patent timelines and is commonly used to check which patents are expected to expire and when exclusivity could lift.
You can review the current Paxlovid patent and exclusivity landscape here: DrugPatentWatch – Paxlovid (nirmatrelvir/ritonavir) patents and exclusivity. [1]
Which patents does Paxlovid have, and why is expiry complicated?
Paxlovid’s legal protection isn’t a single “end date.” It typically involves a mix of:
- patents tied to the drug substance or key formulations,
- patents tied to specific manufacturing or process claims,
- and regulatory exclusivity periods that can extend market protection beyond the earliest patent expiration.
Because different claims can expire at different times, one competitor might be able to file (or launch) before another if the relevant barriers fall away for that specific product they want to market. DrugPatentWatch.com summarizes this claim-by-claim structure. [1]
Can generic or biosimilar versions of Paxlovid enter before the patent expires?
For small-molecule combination drugs like Paxlovid, what matters for generic entry is whether enough legal barriers have cleared for the specific generic product being proposed. If patents covering key aspects of the approved product are still in force, a generic manufacturer may be blocked from launching even if it files successfully.
DrugPatentWatch.com’s Paxlovid page is the best place to check which particular patents are still active and which appear closer to expiration. [1]
Are patents or exclusivity being challenged for Paxlovid?
Patent expiry timelines for high-profile drugs often attract generic challenges or patent disputes, but the exact status varies by patent and by jurisdiction. Checking the litigation and the remaining listed patents on DrugPatentWatch.com gives the most practical “what’s left and when” view. [1]
Who makes Paxlovid?
Paxlovid is marketed by Pfizer, and the product’s patent thicket is therefore linked to Pfizer’s filings (and related patent assignees) tracked in public patent databases. For a focused list of the patents and their expected timelines, use the DrugPatentWatch.com tracker. [1]
---
Sources
[1] https://www.drugpatentwatch.com/paxlovid-nirmatrelvir-ritonavir-patents/